Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alt a 1 subcutaneous immunotherapy for Alternaria allergy
2010-024440-15Phase 3Completed
- Sponsor
- Laboratorios Diater
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and asthma comparing Alt a 1 immunotherapy with Placebo (2 arms). Primary endpoint: Combined symptom and medication score. Started Jun 2011; status: completed.
02
Drugs
Alt a 1
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2010-024440-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024440-15.